csp xcel

AT A GLANCE·       The Globally Harmonized System of Classification and Labeling of Chemicals (GHS) offers a blueprint for handling hazard information through labels and safety data sheets.·       OSHA raised its penalties related to occupational hazards almost by 1.8% on 15th January 2020. Any violation of the recognized safety standards would cost a chemical manufacturer a whopping fine ranging from $9,639 to $134,937.·       GHS compliance effectively minimizes labor costs owing to fewer accidents and health problems.For any drug or chemical manufacturing company, GHS compliance guide rests on four central pillars: Hazard classification, Chemical Labels, Safety Data Sheets and Employee Training. For chemical companies across the globe, it’s an ongoing challenge to remain compliant with GHS

AT A GLANCE·       The chemical industry has been at the forefront when it comes to dealing with disruptions as it serves a diverse range of sectors and constitutes of different attributes (such as raw materials, quality issues, geographical/ regional safety rules, financial instabilities, so forth.).·       Currently, the impact of Covid-19 on chemical industry can be seen across the globe- disrupted supply chains, demand discrepancies, halted travel and fluctuation in petroleum prices have compelled manufacturers to deal with various chemical industry issues all at once.·       Digitization has disrupted the chemical industry even before the pandemic started and the combined effect has been both challenging and a blessing in disguise for the chemical manufacturers.·       Through the right tools

AT A GLANCE·       In the biotechnology and life sciences industry, the product’s end quality depends on the product lifecycle management process. It is essential to optimize and streamline these processes while making automation an irreplaceable component.·       Apart from the need to expedite adaption of modern-day technology across the board, the biotech industry also evaluates tools that ranks high on ROI.·       The ongoing Covid-19 pandemic has put the biotech industry at the front and center in terms of the need for faster tests and development of a vaccine and/ or therapeutics. This unprecedented set of events has brought forward even more pressing challenges in biotechnology manufacturing.The biotech industry is synonymous with cutting-edge research for

IntroductionThe pharmaceutical market has faced various challenges during COVID-19, including adhering to additional regulatory standards. Due to stringent FDA pharmaceutical regulations, pharma companies always need to stay upto date on their compliance tools. Many pharma manufacturers feel that following best practices and maintaining higher quality standards would turn into a hindrance to business productivity. However, with the right technology strategy , Pharma companies can employ the same standards to increase their overall productivity.On an average, about 4,500 drugs and devices are pulled from U.S. shelves each year.Source: US FDAPlanned and unplanned FDA audits are common in the industry. Companies that don’t meticulously maintain accurate records tend to struggle when an unplanned inspection

AT A GLANCE·       Pharmaceutical research and development is steadily going on the path of digitization and the companies that can leverage this digital transformation will be ahead in the curve.·       R&D digital transformation is not a goal; instead, it is a journey wherein companies would need to strategize their moves for an effective result in terms of cost reduction and manage quality criteria of the medicine.·       R&D constitutes a significant portion of pharmaceutical expenses and by automating, optimizing, and expediting processes through digital technology, pharma companies can turn the corner and get better outcomes of the research.The pharmaceutical industry relies on R&D and clinical research for drug development and efficacy testing. The core of